News Articles http://www.drugdiscoveryonline.com/ Fri, 03 Sep 2010 03:34:00 GMT Cetero Research, the leading early-stage contract research organization (CRO), is launching a series of scientific seminars, "An Accelerated Path to Proof-of-Concept in Drug Development," designed to help pharmaceutical and biotechnology researchers learn the latest innovations in Phase I and IIa clinical trial designs. http://www.drugdiscoveryonline.com/article.mvc/Cetero-Research-Launches-Seminar-Series-On-0001?atc~c=771+s=773+r=001+l=a Fri, 03 Sep 2010 03:34:00 GMT Allosteric modulation company Addex Pharmaceuticals Ltd (SIX: ADXN) announced today that it has observed efficacy in a model of Alzheimer's disease using a recently discovered orally-available drug-candidate. The proprietary molecule specifically inhibits a receptor subtype called the metabotropic glutamate receptor 2 (mGluR2) via negative allosteric modulation (NAM). An Addex mGluR2 NAM is scheduled to enter Phase I clinical testing in healthy volunteers during 2011. http://www.drugdiscoveryonline.com/article.mvc/Addex-Drug-Candidate-Effective-In-Alzheimers-0001?atc~c=771+s=773+r=001+l=a Thu, 02 Sep 2010 13:10:18 GMT ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) is pleased to announce a new line of products to be launched in the autumn of 2010, offering neuronal cells derived from human iPS (induced pluripotent stem) cells http://www.drugdiscoveryonline.com/article.mvc/ReproCELL-Announces-New-Line-Of-Services-In-0001?atc~c=771+s=773+r=001+l=a Thu, 02 Sep 2010 04:37:00 GMT The World Economic Forum recently announced that Adimab has been selected as a 2011 Technology Pioneer. To be selected as a World Economic Forum Technology Pioneer, a company must be involved in the development of a major technology or innovation and have the potential for long-term impact on business and society http://www.drugdiscoveryonline.com/article.mvc/Adimab-Selected-As-Technology-Pioneer-2011-0001?atc~c=771+s=773+r=001+l=a Wed, 01 Sep 2010 13:05:00 GMT BIOCIUS Life Sciences Inc., developers of the RapidFire high-throughput mass spectrometry system, today announced a new contract research service that expands the in vitro ADME (Absorption, Distribution, Metabolism and Excretion) assays that can be analyzed quickly and efficiently using RapidFire technology http://www.drugdiscoveryonline.com/article.mvc/BIOCIUS-Life-Sciences-Expands-Contract-0001?atc~c=771+s=773+r=001+l=a Wed, 01 Sep 2010 12:23:00 GMT Golden Helix, Inc., a global leader in genetic analysis solutions, today announced that it has entered into an agreement with CloudScientific, a Chinese life sciences software company, to act as a distributor of the company's analytic services and proprietary software, the SNP & Variation Suite http://www.drugdiscoveryonline.com/article.mvc/Golden-Helix-Partners-With-CloudScientific-0001?atc~c=771+s=773+r=001+l=a Tue, 31 Aug 2010 13:00:00 GMT TPP Global Development Ltd (TPP) announced an agreement with the University of Edinburgh to collaborate on the development of novel pre-clinical intellectual property originated within the University. TPP and the University of Edinburgh will focus on commercialisation opportunities in the areas of nervous system disorders, immunology/inflammation and oncology http://www.drugdiscoveryonline.com/article.mvc/TPP-Global-Development-Ltd-Enters-Into-An-0001?atc~c=771+s=773+r=001+l=a Tue, 31 Aug 2010 09:27:00 GMT KYTHERA Biopharmaceuticals, Inc. ("KYTHERA") and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada. http://www.drugdiscoveryonline.com/article.mvc/KYTHERA-And-Bayer-Dermatology-Unit-Intendis-0001?atc~c=771+s=773+r=001+l=a Mon, 30 Aug 2010 16:30:00 GMT Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), today announced it has initiated a Phase III clinical trial to evaluate tasimelteon in patients with Non-24-Hour Sleep Wake Disorder (N24HSWD), a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness. http://www.drugdiscoveryonline.com/article.mvc/Vanda-Pharmaceuticals-Initiates-Phase-III-0001?atc~c=771+s=773+r=001+l=a Thu, 26 Aug 2010 10:33:00 GMT OpenEye Scientific Software, Inc., the developer of innovative molecular modeling and cheminformatics solutions for drug discovery, announced the first release of the Docking TK as part of the OpenEye Toolkit v1.7.4 release http://www.drugdiscoveryonline.com/article.mvc/New-Toolkit-For-Docking-Released-By-OpenEye-0001?atc~c=771+s=773+r=001+l=a Tue, 24 Aug 2010 16:20:00 GMT BioScale Inc., an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, recently announced the first shipment and installation of the ViBET Protein Analysis Workstation at a major Massachusetts-based pharmaceutical company http://www.drugdiscoveryonline.com/article.mvc/BioScale-Announces-First-Installation-Of-The-0001?atc~c=771+s=773+r=001+l=a Tue, 24 Aug 2010 12:30:00 GMT Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, has announced the launch of Version 7.0 of GastroPlus, the industry's gold standard software for the simulation of drug absorption, pharmacokinetics, and pharmacodynamics http://www.drugdiscoveryonline.com/article.mvc/Simulations-Plus-Releases-GastroPlus-Version-0001?atc~c=771+s=773+r=001+l=a Tue, 24 Aug 2010 12:00:00 GMT Instem, a leading provider of early drug development software solutions, announced recently it has signed a global partnership agreement with SAS, the leader in business analytics software and services. The partnering arrangement enables Instem to more cost effectively license its clients directly for SAS technology embedded within its Provantis preclinical software suite http://www.drugdiscoveryonline.com/article.mvc/Instem-Announces-Global-Partnership-Agreement-0001?atc~c=771+s=773+r=001+l=a Thu, 19 Aug 2010 14:00:00 GMT Scancell Holdings Plc, the developer of therapeutic cancer vaccines, and Cancer Research Technology Ltd ('CRT') - Cancer Research UK's commercialisation and development arm recently announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7. http://www.drugdiscoveryonline.com/article.mvc/Antibody-Licence-Agreement-With-Cancer-0001?atc~c=771+s=773+r=001+l=a Tue, 10 Aug 2010 07:39:00 GMT TrackWise SelectStart is a purpose-built quality management solution created specifically for small to medium size companies across different segments of life science industries. http://www.drugdiscoveryonline.com/article.mvc/New-Quality-Management-Software-Created-0001?atc~c=771+s=773+r=001+l=a Mon, 09 Aug 2010 04:47:00 GMT Cypress Bioscience, Inc., a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system disorders, today announced that it is discontinuing its rights under its agreement with Forest Laboratories to co-promote SavellaŽ, its drug for fibromyalgia http://www.drugdiscoveryonline.com/article.mvc/Cypress-Bioscience-Announces-Agreement-To-0001?atc~c=771+s=773+r=001+l=a Wed, 04 Aug 2010 08:34:00 GMT New Earth BioMed, a new 501(c)3 nonprofit corporation, has launched a long-term drug discovery program to identify mixtures of nontoxic plant compounds useful in treating cancer. An estimated 77 percent of approved cancer and anti-infective drugs in the United States are either natural products or are derived from them http://www.drugdiscoveryonline.com/article.mvc/New-Earth-BioMed-Launches-Natural-Product-0001?atc~c=771+s=773+r=001+l=a Wed, 04 Aug 2010 04:04:00 GMT Five Prime Therapeutics, Inc. (FivePrime), a leader in the discovery and development of innovative biologics announced today that it has formed a focused strategic drug discovery alliance with GlaxoSmithKline. This new collaboration gives GSK exclusive access to FivePrime's drug discovery platforms specifically in the areas of sarcopenia, cachexia and other skeletal muscle disorders. Under the terms of the agreement, GSK will receive access to FivePrime's comprehensive proprietary collection of secreted proteins and transmembrane http://www.drugdiscoveryonline.com/article.mvc/Five-Prime-Therapeutics-Inc-Announces-0001?atc~c=771+s=773+r=001+l=a Tue, 03 Aug 2010 18:30:00 GMT PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, recently announced that it has acquired VisEn Medical, Inc., an in vivo molecular imaging technology company based in Bedford, Massachusetts http://www.drugdiscoveryonline.com/article.mvc/PerkinElmer-To-Acquire-VisEn-Medical-Inc-0001?atc~c=771+s=773+r=001+l=a Tue, 03 Aug 2010 12:00:00 GMT Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, has announced the launch of its MedChem Studio software for drug discovery http://www.drugdiscoveryonline.com/article.mvc/Simulations-Plus-Launches-MedChem-Studio-0001?atc~c=771+s=773+r=001+l=a Tue, 03 Aug 2010 12:00:00 GMT